01 NPHLA Intelligence desk
For weight-loss clinics, med spas, pharmacists, prescribers, medical directors and metabolic-health operators: what is changing in GLP-1 and next-generation obesity medicine — and what it could mean for your practice.
Featured on this desk
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
NPHLA tracked 15 new official records on this desk today: 2 new studies, 13 trial updates.
Automated from official records13 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records2 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records11 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records9 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records3 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records3 sources1 min read
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records4 sources1 min read
Phase 1, Korea United Pharm. Inc.. Conditions: Bioequivalence; Pharmacokinetics. Interventions: Semaglutide (UI112); Semaglutide (UIC202611). Investigational: trial-stage therapies are not approved for the use studied.
Phase 3, BrightGene Bio-Medical Technology Co., Ltd.. Previously “Active, not recruiting”. Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC; Drug: Semaglutide Administered SC. Investigational: tr…
Phase 1, Hangzhou Sciwind Biosciences Co., Ltd.. Conditions: Food Effect in Healthy Volunteers; Weight Management. Interventions: Dose 1; Dose 2. Investigational: trial-stage therapies are not approved for the use studied.
Not applicable, Lembas. Conditions: Appetite and Hunger, Suppression; Satiety and Appetite; Weight Change; Gastrointestinal Symptoms; Body Composition. Interventions: Lembas Edge™; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Phase 3, Novo Nordisk A/S. Conditions: Type 2 Diabetes. Interventions: Zenagamtide; Semaglutide; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
